FLAGSTAFF, Arizona | January 6, 2026 — W. L. Gore & Associates has secured U.S. FDA approval for the GORE® VIABAHN® FORTEGRA Venous Stent, marking a first-of-its-kind regulatory milestone for the treatment of deep venous disease in the inferior vena cava (IVC) and iliofemoral veins. The approval represents a major advancement in vascular MedTech innovation, addressing one of the most complex and underserved areas in venous intervention.
Science Significance
The FORTEGRA Venous Stent introduces a novel engineering approach designed specifically for deep venous anatomy, combining an open-structure, self-expanding nitinol frame with an expanded polytetrafluoroethylene (ePTFE) polymer lattice. This design enables an optimal balance of conformability and compression resistance, allowing the stent to adapt to natural venous anatomy while maintaining structural integrity under external compression. This tailored design overcomes long-standing limitations of arterial stents repurposed for venous use, particularly in large-diameter vessels such as the IVC and across the iliocaval confluence, where flow dynamics and side-branch preservation are critical.
Regulatory Significance
From a cGxP and regulatory affairs perspective, the approval is highly significant as the device received FDA Breakthrough Device designation, accelerating its development and review. The designation underscores the unmet medical need and clinical importance of treating extensive venous obstruction. The approval was supported by a prospective, international clinical trial—the first of its kind to include IVC, iliac, and iliofemoral veins—demonstrating compliance with stringent FDA safety and efficacy requirements. This milestone reinforces FDA’s increasing focus on innovation within regulated medical devices, setting a benchmark for future venous technologies under evolving Quality Management System Regulations (QMSR).
Business Significance
Advertisement
For Gore, the approval strengthens its leadership position in the global vascular device market and expands the VIABAHN® device portfolio into a new, high-complexity therapeutic segment. The FORTEGRA Venous Stent targets patients with extensive thrombotic disease burden, a population previously lacking devices specifically designed for their anatomy. Commercially, the approval unlocks new hospital, payer, and physician adoption opportunities, while reinforcing Gore’s reputation for quality, reliability, and long-term product performance. Backed by a legacy of over 55 million implanted medical devices, this approval enhances Gore’s strategic growth in regulated MedTech markets.
Patients’ Significance
For patients, this approval represents a transformational clinical advance. The pivotal trial demonstrated a 12-month primary patency rate of 83.4%, despite the inclusion of patients with severe disease, including multivessel involvement and post-thrombotic syndrome. Importantly, the study reported no stent migrations, fractures, clinically significant pulmonary embolisms, or device-related deaths, reinforcing the device’s strong safety profile. Patients now gain access to a device designed specifically for deep venous disease, improving long-term vessel patency, reducing reintervention risk, and enhancing quality of life.
Policy Significance
At a policy level, the approval highlights the effectiveness of FDA’s Breakthrough Devices Program in bringing high-impact medical technologies to patients faster without compromising safety or data integrity. It also signals growing regulatory recognition of venous disease as a serious, debilitating condition requiring purpose-built solutions. For healthcare systems and payers, the availability of a validated, indication-specific venous stent may support evidence-based reimbursement decisions and improved standard-of-care guidelines for complex venous obstruction.
The FDA approval of the GORE® VIABAHN® FORTEGRA Venous Stent marks a landmark moment in venous intervention, uniting scientific innovation, regulatory rigor, and patient-centric design. For the cGxP community, it exemplifies how robust clinical evidence, quality manufacturing, and regulatory alignment can successfully deliver first-in-class medical devices. As venous disease gains greater clinical and policy attention, this approval sets a new standard for MedTech development and compliance-driven innovation.
Source: W. L. Gore & Associates, Inc. MPD Division press release
